Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
The FDA granted orphan drug designation to deupirfenidone, also known as LYT-100, for treating patients with idiopathic pulmonary fibrosis, according to a press release from PureTech Health.The ...
PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis
Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union ...
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone in IPF ...
Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...
The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease marked by irreversible fibrosis and poor prognosis. Growing disease awareness and improved diagnostics are expanding the ...
HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...
Idiopathic pulmonary fibrosis represents a high need specialty market, with global IPF drug sales of roughly USD 3 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results